

Remarks


The foregoing amendments to the specification are to insert the priority provisional application information, for which this application claims benefit. The Abstract has also been added as a separate sheet, and should be inserted following the claims in the specification.

The cancellation to the claims 10-13 and 16-27 are to reduce the number of claims in the present application for prosecution. The amendments to claims 3-5 to eliminate multiple dependencies and to place the claims in proper format. No new matter has been added.

Respectfully submitted,

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(617) 871-3346
Encl.: Abstract

Date: *February 10, 2006*


John T. Prince
Attorney for Applicants
Reg. No. 43,019